.jpg?format=webp&width=780)
The study reports primary results from LEROS, a Phase 4, externally controlled interventional study in patients with chronic LHON (1 to ≤5 years since onset) treated with idebenone for up to 24 months. As was observed in the subacute/dynamic phase, the frequency of a CRB from baseline at 12 months was significantly higher in treated, chronic eyes than in matched NH eyes. LEROS provides evidence of a significant therapeutic benefit of idebenone treatment in patients with LHON in the chronic stage up to 5 years from onset.
Like
Save
Share